Methotrexate CAS#59-05-2

Methotrexate CAS#59-05-2

Methotrexate CAS#59-05-2

Broad Anti-Tumor Activity: It is effective against multiple cancers, including leukemia, lymphoma, lung cancer, breast cancer, cervical cancer, and osteosarcoma.


Wide Clinical Application Scope: It is used in the treatment of various malignant diseases such as squamous cell carcinoma, choriocarcinoma, and hydatidiform mole.


Rapid Elimination from the Body: Approximately 90% of the drug is excreted in urine within 12 hours after oral administration, indicating fast metabolic clearance.


Defined Pharmacological Profile: It has a known active metabolite (7-hydroxymethotrexate) and documented toxicity data (rat intravenous LD50: 14 mg/kg), supporting its studied pharmacokinetic characteristics.

Quality Assurance

Rigorous quality control and full regulatory compliance assured.

Sustainable Development

Sustainable processes cut waste, lower emissions, and save costs.

Specialty Solutions

Tailored fine chemicals that enhance efficiency and outcomes.

Chemical Manufacturer

A trusted manufacturer capable of stable, high-volume production and supply.

ABOUT THE PRODUCT

Product Description

Product Description-Methotrexate CAS#59-05-2


Methotrexate is an effective antitumor agent for acute lymphoblastic leukemia, lymphoma, malignant hydatidiform mole, choriocarcinoma, squamous cell carcinoma, lung, cervical, breast cancer and osteosarcoma. After oral dosing, around 90% of the parent drug is excreted in urine within 12 hours; its primary metabolite is 7-hydroxymethotrexate. The intravenous LD₅0 in rats is 14 mg/kg.

Product Applications-Methotrexate CAS#59-05-2


This agent is an effective anti-tumor drug, used in the treatment of conditions such as acute lymphoblastic leukemia, lymphoma, malignant hydatidiform mole, choriocarcinoma, squamous cell carcinoma, lung cancer, cervical cancer, breast cancer, and osteosarcoma. Following oral administration, 90% of the parent drug is excreted in the urine within 12 hours; its primary metabolite is 7-hydroxymethotrexate.

ABOUT THE PRODUCT

Product Data

Chemical Properties-Methotrexate CAS#59-05-2



Density

1.536

Melting point

195℃

Boiling point

561.26°C (rough estimate)

Refractive index

1.6910 (estimate)

Flash Point

11℃

Precise Quality

454.171

PSA

210.54

logP

1.8217

Solubility

H2O: insoluble

Appearance

yellow crystalline powder

Storage

Store at -20°C. Hygroscopic. Light Sensitive.

Color/Form

Pale-yellow to Yellow-brown Solid

Decomposition

When heated to decomposition it emits toxic fumes including /nitrogen oxides/.

pKa

pKa 3.04/4.99(H2O,t =25,I=0.0025) (Uncertain)

Water Solubility

Insoluble.

Spectral Properties

Specific optical rotation: 20.4 + or - 0.6 deg at 21 deg C/589 D (concentration by 0.1 N sodium hydroxide) maximum absorption: 243nm, A1= 388;307 nm, A1 = 475 (in 0.1 n hydrogen chloride). 258 nm, A1= 544; 303 nm, A1= 546; 372 nm, A1= 177 (in 0.1 N sodium hydroxide)UV max (0.1N HCl) 244, 307 nm; UV max (0.1N NaOH) 257, 302, 370 nm

Stability

Stable, but light sensitive and hygroscopic. Incompatible with strong acids, strong oxidizing agents. Store at -15C or below.

StorageTemp

−20°C



Safety Information-Methotrexate CAS#59-05-2



Hazard Codes

T,F

Risk Statements

61-25-36/38-46-39/23/24/25-23/24/25-11

Safety Statements

53-26-36/37-45-36/37/39-36-16

RIDADR

UN 2811 6.1/PG 3

WGK Germany

3

RTECS

MA1225000

F

3-8-10

TSCA

TSCA listed

HazardClass

6.1(b)

PackingGroup

III

HS Code

29335995

Storage Class

6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Hazard Classifications

Acute Tox. 3 OralMuta. 2Repr. 1BSTOT RE 1

Hazardous Substances Data

59-05-2(Hazardous Substances Data)

Toxicity

LD50 oral in rat: 135mg/kg


ABOUT US

Shipped From the Factory

产品详情

ABOUT THE PRODUCT

Contact Us

Submit

ABOUT US

Related Products